Alcon has officially completed its acquisition of LumiThera, expanding our Retina portfolio with the Valeda® photobiomodulation (PBM) device. We look forward to broadening access to this non-invasive and efficacious treatment to dry AMD patients*⁽¹⁻²⁾, as we continue to address unmet needs in eye care. Learn more: http://spr.ly/6183ABueD #Alcon #Retina #AMD *Dry AMD eyes with: 3 medium drusen, or 1 large drusen, or non-central involving GA; and with BCVA between 20/32 – 20/70 (i.e., early and in